Skip to main content

John Saringer tinkers with a Venowave, a calf pump he invented that reduces swelling and increases circulation, in the lab at his house in Stouffville, Ont.

Matthew Sherwood/The Globe and Mail

Innovators at Work is a contest to recognize talented people who not only have great ideas but also turn them into reality through their drive and their actions. You can nominate an Innovator here.

As a young mechanical engineering student at the University of Toronto in the 1970s, John Saringer was, as he put it, "successfully avoiding getting a real job" and looking to get his teeth into something that could lead to a career.

That's when a meeting with Robert Salter, then a world leader in pediatric orthopedic surgery at The Hospital for Sick Children in Toronto, gave Mr. Saringer the direction he was looking for. Using Dr. Salter's research, Mr. Saringer designed a therapy device for use in the first phase of rehabilitation following joint surgery. He then formed Toronto Medical Corp. to build and sell the equipment to more than 50 countries worldwide.

Story continues below advertisement

Though that company was sold in 1997, Mr. Saringer's work in the medical community continued when he encountered clinician Jack Hirsh of McMaster University in Hamilton shortly afterward and was asked to help his research in the field of hematology and blood clotting. Mr. Saringer then spent much of the next 10 years conceptualizing and devising the Venowave, a compression pump for treating and alleviating the symptoms associated with poor circulation.

"When I started with Bob Salter, I thought it was a good idea, I felt it was a worthwhile thing to do," says the 59-year-old Mr. Saringer, who holds more than 30 patents worldwide. "I didn't know where it would lead, whether it would result in a business or not, but I thought it would and … what really turned me on was to build products, see them applied to patients and see them make a difference."

Mr. Saringer has since launched Saringer Life Science Technologies Inc., for which he also devised the IceOtherm, a pen-like device that uses both hot and cold therapies to reduce pain in any applied area. Mr. Saringer, a former president of Mensa Canada, credits his innovative abilities to the power of a creative mind.

"I think I have a unique ability, which is not common, which is the ability to visualize products in my head without building them," he explains. "So when Dr. Salter or somebody else tells me a problem, I basically [come up with] 10, 20, 30 different approaches and in my mind I try to sort out which of them are most likely to achieve the objective and be cost-effective to make. And then I develop along that path. But most of the process actually occurs in my imagination."

Mr. Saringer, who was in Milwaukee last week to promote his products, also knows that if his innovations are going to go anywhere, they have to be accepted south of the border.

"Once we're well established here (in the United States) we're pretty certain we'll see a lot of success elsewhere, including Canada," he says. "In Canada, the irony is, if you can say your product is being used in the Mayo Clinic, then they say, 'Well, it must be good.'

"It would be a mistake to tell a Canadian doctor that it's made in Canada because that actually doesn't mean anything; it's how you're doing in the U.S. that matters a whole lot more."

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies